| 2,346 | 112 | 27 |
| 下载次数 | 被引频次 | 阅读次数 |
中国仍然是全球乙型病毒性肝炎(乙肝)高流行的国家之一。本文阐述了中国乙肝的疾病负担现状、预防控制策略与成就、存在问题和展望。
Abstract：China has one of the largest burdens of hepatitis B in the world. In this article, we review the current hepatitis B burden and discuss strategies, achievements, challenges, and prospects for hepatitis B prevention and control in China.
[1]World Health Organization.Global health sector strategy on viral hepatitis 2016-2021[EB/OL].(2016-06-01)[2016-07-03].http://www.who.int/hepatitis/strategy2016-2021/ghss-hep/en/.
[2]翟祖一.我国乙型肝炎表面抗原和表面抗体分布状况的流行病学研究[J].中华微生物学和免疫学杂志,1986,增刊号(病毒性肝炎专辑):20-40.ZHAI Zuyi.An epidemiology study on the distribution of HBsAg and anti-HBs in China[J].Chinese Journal Microbiology and Immunology,1986,Suppl(special issue viral hepatitis):20-40.
[3]戴志澄,祁国明.中国病毒性肝炎血清流行病学调查(上卷)1992~1995[M].北京:科学技术文献出版社,1997.DAI Zhicheng,QI Guoming.Viral hepatitis in Chinaseroepidemiological survey in Chinese population(part one),1992-1995[M].Beijing:Science and Technical Documentation Press,1997.
[4]CUI Fuqiang,SHEN Liping,LI Li,et al.Prevention of chronic hepatitis B after 3 decades of escalating vaccination policy,China[J].Emerg Infect Dis,2017,23(5):765-772.
[5]World Health Organization.Hepatitis B key facts[EB/OL].(2018-07-18)[2019-04-20].https://www.who.int/news-room/fact-sheets/detail/hepatitis-b.
[6]The Polaris Observatory Collaborators.Global prevalence,treatment,and prevention of hepatitis B virus infection in2016:a modelling study[J].Lancet Gastroenterol Hepatol,2018,3(6):383-403.
[7]赵铠,章以浩.中国生物制品发展史略1910~1990[M].北京:北京集惠印刷有限责任公司,2003.ZHAO Kai,ZHANG Yihao.The development history of biological products in China,1910-1990[M].Beijing:Beijing Jihui Printing Co.LTD,2003.
[8]中华人民共和国卫生部.2006年~2010年全国乙型病毒性肝炎防治规划[J].中国实用乡村医生杂志,2006,13(8):1-5.Ministry of Health.National plan for hepatitis B prevention and treatment,2006-2010[J].Chinese Journal of Practical Rural Doctor,2006,13(8):1-5.
[9]WANG Ailing,QIAO Yaping,WANG Linhong,et al.Integrated prevention of mother-to-child transmission for human immunodeficiency virus,syphilis and hepatitis B virus in China[J].Bull World Health Organ,2015,93(1):52-56.
[10]World Health Organization.Regional framework for the triple elimination of mother-to-child transmission of HIV,hepatitis B and syphilis in Asia and the Pacific 2018-2030[EB/OL].(2018-10-8)[2019-05-03].https://iris.wpro.who.int/bitstream/handle/10665.1/14193/9789290618553-eng.pdf?ua=1.
[11]LI Ling,LI Kayi,YAN Ke,et al.The history and challenges of blood donor screening in China[J].Transfus Med Rev,2017,31(2):89-93.
[12]GAO Zhen,LIU Jing,FU Ping,et al.Estimation of hepatitis B-positive rates in Chinese blood donors by combining predonation and postdonation screening results[J].Transfusion,2019,59(5):1749-1754.
[13]LIU Jue,LIANG Wannian,JING Wenzhan,et al.Countdown to 2030:eliminating hepatitis B disease,China[J].Bull World Health Organ,2019,97(3):230-238.
[14]齐小秋,王宇.全国人群乙型病毒性肝炎血清流行病学调查报告[M].北京:人民卫生出版社,2011.QI Xiaoqiu,WANG Yu.Report on the serosurvey of viral hepatitis B in China[M].Beijing:People's Medical Publishing House,2011.
[15]LIANG Xiaofeng,BI Shengli,YANG Weizhong,et al.Evaluation of the impact of hepatitis B vaccination among children born during 1992-2005 in China[J].The Journal of Infectious Diseases,2009,200(1):39-47.
[16]LIANG Xiaofeng,BI Shengli,YANG Weizhong,et al.Epidemiological serosurvey of hepatitis B in Chinadeclining HBV prevalence due to hepatitis B vaccination[J].Vaccine,2009,27(47):6550-6557.
[17]WOODRING J,PASTORE R,BRINK A,et al.Progress toward hepatitis B control and elimination of mother-tochild transmission of hepatitis B virus-Western Pacific Region,2005-2017[J].MMWR,2019,68(8):195-200.
[18]张国民,缪宁,郑徽,等.中国2005-2016年乙型病毒性肝炎报告发病的年龄和地区特征[J].中国疫苗和免疫,2018,24(2):121-126.ZHANG Guomin,MIAO Ning,ZHENG Hui,et al.Incidence by age and region of hepatitis B reported in China from 2005 to 2016[J].Chinese Journal of Vaccines and Immunization,2018,24(2):121-126.
[19]LIANG Peifeng,ZU Jian,YIN Juan,et al.The independent impact of newborn hepatitis B vaccination on reducing HBV prevalence in China,1992-2006:a mathematicalmodel analysis[J].Journal of Theoretical Biology,2015,386(1):115-121.
[20]张顺祥,党如波,张卫东,等.中国乙型肝炎疫苗免疫预防效果和现行策略的经济学和决策学评估[J].中华流行病学杂志,2008,29(10):1003-1008.ZHANG Shunxiang,DANG Rubo,ZHANG Weidong,et al.Analysis on economic efficacy regarding previous strategies and current recommendations for vaccination against hepatitis B virus in China[J].Chinese Journal of Epidemiology,2008,29(10):1003-1008.
[21]张顺祥,孙盼盼,夏云.我国2006-2030年乙肝免疫预防经济学效果的评价和预测[J].中华疾病控制杂志,2018,22(7):741-746.ZHANG Shunxiang,SUN Panpan,XIA Yun.Evaluation and forecast for economic outcomes of hepatitis B immunoprophylaxis strategies in China from 2006 to2030[J].Chinese Journal of Disease Control&Prevention,2018,22(7):741-746.
[22]国家卫生和计划生育委员会.关于公布国家药品价格谈判结果的通知[EB/OL].(2016-05-20)[2019-04-20].http://www.nhc.gov.cn/yaozs/s7655/201605/58c5bcled0f14c75b8f15flc149b35f4.shtml.National Health and Family Planning Commission.Notice of issuing the result of national drug price negotiation[EB/OL].(2016-05-20)[2019-04-20].http://www.nhc.gov.cn/yaozs/s7655/201605/58c5bcled0f14c75b8f15flc149b35f4.shtml.
[23]朱佳英,任晋文,华恃彬."4+7"城市药品带量采购在公立医院的实施效果预测与探讨[J].浙江医学,2019,41(10):1103-1107.ZHU Jiaying,REN Jinwen,HUA Shibin.Prediction and discussion on the implementation effect of “4+7” urban drug procurement in governmental hospitals[J].Zhejiang Medical Journal,2019,41(10):1103-1107.
[24]PAN CQ,DU AN ZP,DAI EH,et al.Tenofovir to prevent hepatitis B transmission in mothers with high viral load[J].The New England Journal of Medicine,2016,374(24):2324-2334.
[25]中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2015年版)[J].临床肝胆病杂志,2015,31(12):1491-1960.Hepatology Society of Chinese Medical Association,Infectious Disease Society of Chinese Medical Association.The guideline of prevention and treatment for chronic hepatitis B:a 2015 update[J].Journal of Clinical Hepatology,2015,31(12):1491-1960.
[26]中国肝炎防治基金会,中华医学会感染病学分会,中华医学会肝病学分会.乙型肝炎母婴阻断临床管理流程[J].临床肝胆病杂志,2017,33(7):1214-1217.Chinese Foundation for Hepatitis Prevention and Control,Infectious Disease Society of Chinese Medical Association,Hepatology Society of Chinese Medical Association.Management algorithm for interrupting mother-tochild transmission of hepatitis B[J].Journal of Clinical Hepatology,2017,33(7):1214-1217.
基本信息:
DOI：10.19914/j.cjvi.2019.05.001
中图分类号:R512.62;R181.8
引用信息:
[1]王富珍,郑徽,孙校金,等.中国控制乙型病毒性肝炎的成就与展望[J].中国疫苗和免疫,2019,25(05):487-492.DOI:10.19914/j.cjvi.2019.05.001.
基金信息:
国家科技重大专项“中国慢性病毒性肝炎流行现状研究”课题(2017ZX10105015)
2019-07-03
2019
2019-10-15
2019
1
2019-09-20
2019-09-20
2019-09-20